<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948610</url>
  </required_header>
  <id_info>
    <org_study_id>NHLBI RO1 HL079955</org_study_id>
    <secondary_id>NHLBI RO1 HL079955</secondary_id>
    <nct_id>NCT00948610</nct_id>
  </id_info>
  <brief_title>Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy</brief_title>
  <official_title>Sleep &amp; Immune Mechanisms in Rheumatoid Arthritis: Remicade Substudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than half of rheumatoid arthritis (RA) patients complain of sleep disturbance and this
      cardinal complaint is associated with fatigue, pain, and depressed mood in patient with
      chronic inflammatory disorder. Despite the frequency of this complaint, there is limited
      efforts to evaluate sleep or the abnormal increases in the expression of pro-inflammatory
      cytokines play a key role in the progression of RA, we hypothesize that the cytokine network
      is one physiological system that is associated with sleep disturbances in RA patients.
      Pro-inflammatory cytokines signal the central nervous system and are associated with
      increased symptoms of pain, fatigue, and depressed mood in rheumatic patients. The specific
      aims of the study are to examine the contribution of cytokines on sleep by administering a
      TNF antagonist vs. placebo to probe the action of pro-inflammatory cytokines on sleep in RA
      Patients. Examination of sleep and its consequences for pro-inflammatory cytokine activity
      within the framework of an observational and experimental research design will have
      implications for understanding the psycho-biological mechanisms that link sleep and the
      clinical manifestations of RA. Results from this study will guide the developments of
      interventions that target disordered sleep with potential effects on disability in RA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abnormal sleep is reported by more than half of rheumatoid arthritis patients, in addition to
      the traditional symptoms associated with the disease, such as morning stiffness, pain, and
      functional debility. When recording brain activity during sleep using electroencephalography
      or EEG. Sleep abnormalities have been found independent of pain and thus the mechanisms to
      account for disordered sleep in this population are unknown. The immune system, via
      pro-inflammatory cytokines, plays a major role in the development of rheumatoid arthritis.
      Pro-inflammatory cytokines are molecules that act as signals to stimulate activity of
      different arms of the immune system. New medications such as remicade (infliximab) have been
      developed which slow disease activity by blocking the activity of these pro-inflammatory
      cytokines. This is done by binding to the cytokine TNF and rendering it biologically
      inactive. Pro-inflammatory cytokines also appear to play a role in sleep. A number of basic
      and human studies have found that cytokines and sleep exhibit a bi-directional relationship.
      However, no study to date has explored this relationship in a rheumatoid arthritis
      population. Thus, this research study has the potential to test whether cytokines influence
      sleep in rheumatoid arthritis. We will determine if a single dose of a pro-inflammatory
      cytokine blocking medication (remicade) affects sleep in rheumatoid arthritis patients.
      Interested participants will undergo an eligibility interview to review in-depth subject
      participation, RA diagnosis, written Consent. Following eligibility, patients will undergo a
      single overnight sleep assessment lasting four nights at the General Clinical Research
      Center. After the adaption and baseline nights, on day 3, patients will be randomized to
      receive either 10 mg/kg of remicade or placebo and their sleep will be subsequently monitored
      for two additional nights ( post-infusion 1 and post-infusion 2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Slow Wave Sleep</measure>
    <time_frame>Post-infusion day 2</time_frame>
    <description>Slow wave sleep in minutes at post-infusion day 2 in placebo vs. remicade</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular Inflammation</measure>
    <time_frame>Post-infusion day 2</time_frame>
    <description>Percentage of monocytes producing interleukin-6 at post-infusion day 2 in placebo vs. remicade</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo—participant will receive placebo saline solution via IV route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remicade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remicade—Participant will be given 10 mg/kg of drug via IV route.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remicade</intervention_name>
    <description>Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Remicade</arm_group_label>
    <other_name>Infliximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Rheumatoid arthritis patients will meet American College of Rheumatology revised
             criteria (Arnett, Edworthy et al. 1988). This requires at least four of the following
             seven criteria: 1) morning joint stiffness; 2) arthritis in 3 or more joint areas; 3)
             arthritis of hand joints; 4) symmetric arthritis; 5) rheumatoid nodules; 6) presence
             of serum rheumatoid factor and 7) changes on posteroanterior hand and wrist
             radiographs. In addition, criteria 1-4 must be present for at least four weeks.
             Subjects must be between 18 and 85 years of age.

          2. If rheumatoid arthritis patients are receiving treatment with traditional disease
             modifying antirheumatic drugs (DMARD), such as methotrexate, sulfasalazine or
             hydroxychloroquine, they must be on a stable regime for one month before study and
             stable throughout study.

          3. If rheumatoid arthritis patients have received treatment with a TNF antagonist or
             other biologic medication, they must be drug free for greater than 3 months.

        Exclusion Criteria:

          1. Steroids - Individuals currently taking greater than an equivalent of 10 mg of
             prednisone will be excluded given the potent anti-inflammatory effects of such
             medications.

          2. Opioids - Individuals using multiple daily dosage schedule of opioid agents such as
             oxycodone (Percocet), hydrocodone (Vicodin), morphine, Dilaudid will be excluded.

          3. Co-morbid medical disorders - the presence of active unstable and uncontrolled
             co-morbid medical conditions such as diabetes, cardiovascular diseases, and cancer
             will be exclusionary criteria. In particular, individuals with co-morbid inflammatory
             disorders such as Crohn's disease and ulcerative colitis and other autoimmune
             disorders will be excluded. Any uncontrolled medical condition that is deemed by the
             investigators to interfere with the proposed study procedures, or put the study
             participant at undue risk will also be considered exclusionary criteria.

          4. Chronic infections - individuals with chronic infections will also be excluded because
             of effects on immune markers measured in study.

          5. Co-morbid pain disorders - individuals with co-morbid pain disorders such as
             fibromyalgia will also be excluded. Individuals with fibromyalgia have been found to
             have sleep abnormalities as well as daytime fatigue and pain and thus could confound
             findings.

          6. Psychiatric disorders - current conditions such as major depressive disorder, bipolar
             disorder and risk for suicide will also be considered exclusionary criteria.

          7. Gender-based criteria - pregnant or breast-feeding women will also be excluded because
             of their effects on neuroendocrine systems and sleep
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Irwin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles, General Clinical Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cousinspni.org/</url>
    <description>UCLA Cousins Center for PNI</description>
  </link>
  <reference>
    <citation>Irwin MR, Wang M, Ribeiro D, Cho HJ, Olmstead R, Breen EC, Martinez-Maza O, Cole S. Sleep loss activates cellular inflammatory signaling. Biol Psychiatry. 2008 Sep 15;64(6):538-40. doi: 10.1016/j.biopsych.2008.05.004. Epub 2008 Jun 17.</citation>
    <PMID>18561896</PMID>
  </reference>
  <reference>
    <citation>Irwin MR, Carrillo C, Olmstead R. Sleep loss activates cellular markers of inflammation: sex differences. Brain Behav Immun. 2010 Jan;24(1):54-7. doi: 10.1016/j.bbi.2009.06.001. Epub 2009 Jun 9.</citation>
    <PMID>19520155</PMID>
  </reference>
  <reference>
    <citation>Irwin MR, Davis M, Zautra A. Behavioral Comorbidities in Rheumatoid Arthritis: A Psychoneuroimmunological Perspective. Psychiatr Times. 2008 Aug 1;25(9):1.</citation>
    <PMID>19590742</PMID>
  </reference>
  <reference>
    <citation>Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun. 2008 Jan;22(1):24-32. Epub 2007 Aug 15.</citation>
    <PMID>17706915</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2009</study_first_posted>
  <results_first_submitted>March 24, 2017</results_first_submitted>
  <results_first_submitted_qc>August 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 12, 2017</results_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Michael Irwin, MD</investigator_full_name>
    <investigator_title>Professor in Residence</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo—participant will receive placebo saline solution via IV route.
Remicade: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
        </group>
        <group group_id="P2">
          <title>Remicade</title>
          <description>Remicade—Participant will be given 10 mg/kg of drug via IV route.
Remicade: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo—participant will receive placebo saline solution via IV route.
Remicade: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
        </group>
        <group group_id="B2">
          <title>Remicade</title>
          <description>Remicade—Participant will be given 10 mg/kg of drug via IV route.
Remicade: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.8" spread="14.0"/>
                    <measurement group_id="B2" value="54.1" spread="13.3"/>
                    <measurement group_id="B3" value="51.5" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Slow Wave Sleep</title>
        <description>Slow wave sleep in minutes at post-infusion day 2 in placebo vs. remicade</description>
        <time_frame>Post-infusion day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo—participant will receive placebo saline solution via IV route.
Remicade: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
          </group>
          <group group_id="O2">
            <title>Remicade</title>
            <description>Remicade—Participant will be given 10 mg/kg of drug via IV route.
Remicade: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
          </group>
        </group_list>
        <measure>
          <title>Slow Wave Sleep</title>
          <description>Slow wave sleep in minutes at post-infusion day 2 in placebo vs. remicade</description>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" spread="39.5"/>
                    <measurement group_id="O2" value="67.3" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cellular Inflammation</title>
        <description>Percentage of monocytes producing interleukin-6 at post-infusion day 2 in placebo vs. remicade</description>
        <time_frame>Post-infusion day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo—participant will receive placebo saline solution via IV route.
Remicade: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
          </group>
          <group group_id="O2">
            <title>Remicade</title>
            <description>Remicade—Participant will be given 10 mg/kg of drug via IV route.
Remicade: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
          </group>
        </group_list>
        <measure>
          <title>Cellular Inflammation</title>
          <description>Percentage of monocytes producing interleukin-6 at post-infusion day 2 in placebo vs. remicade</description>
          <units>percentage of monocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.6"/>
                    <measurement group_id="O2" value="4.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo—participant will receive placebo saline solution via IV route.
Remicade: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
        </group>
        <group group_id="E2">
          <title>Remicade</title>
          <description>Remicade—Participant will be given 10 mg/kg of drug via IV route.
Remicade: Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A number of limitations exist: the sample size was relatively small; only women were included; and the exclusive use of infliximab limits generalizability to other TNF antagonists, due to differing biochemical and mechanistic profiles.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael R. Irwin</name_or_title>
      <organization>UCLA</organization>
      <phone>3108258281</phone>
      <email>mirwin1@ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

